Showing results (11-20 of 108) with videos related to
Sort By:
Pageof 11
Arthritis Research & Therapy|March 1, 2008
New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samplesThomas Barnetche, Arnaud Constantin, Alain Cantagrel, et al.Joint Bone Spine|October 5, 2007
Impact of etanercept on the costs of rheumatoid arthritis (RA): results from a French observational studyBlandine Juillard-Condat, Arnaud Constantin, Anne Cambon-Thomsen, et al.Clinical and Experimental Rheumatology|January 24, 2020
Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomesNuma Simons, Yannick Degboé, Thomas Barnetche, et al.Rheumatology (Oxford, England)|June 1, 2023
A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA)Frédéric Lioté, Arnaud Constantin, Étienne Dahan, et al.Rheumatology (Oxford, England)|June 16, 2014
Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysisHuong Nguyen, Adeline Ruyssen-Witrand, Frédérique Gandjbakhch, et al.Journal of Clinical Medicine|July 2, 2020
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid ArthritisYannick Degboé, Michael Schiff, Michael Weinblatt, et al.Joint Bone Spine|September 25, 2016
Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalphaCharlotte Mabille, Yannick Degboe, Arnaud Constantin, et al.RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.Joint Bone Spine|February 15, 2022
Factors associated with drug-free remission at 5-year in early onset axial spondyloarthritis patients: Data from the DESIR cohortAdeline Ruyssen-Witrand, Vanessa Rousseau, Agnès Sommet, et al.Clinical and Experimental Rheumatology|March 4, 2024
Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE studyRené-Marc Flipo, Arnaud Constantin, Philippe Goupille, et al.Pageof 11